Oragenics, Inc.

Latest News

Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections

Innovative Biopharmaceuticals from Oral Science

At Oragenics, we are focused on becoming the world leader in novel antibiotics targeted against some of the most prevalent and urgently needed infectious diseases. We also develop, market and sell proprietary OTC probiotics specifically designed to enhance oral health for humans and pets.

Learn More About Oragenics

Exclusive Collaboration with Intrexon

Our exclusive channel collaboration arrangement with Intrexon contemplates the use of Intrexon’s advanced transgene and cell engineering platforms for the development and production of revolutionary lantibiotics and live biotherapeutic products (LBP).

Learn More About Our Collaborations

Fighting Global Bacterial Antibiotic Resistance

Oragenics, in collaboration with Intrexon, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Learn More About Lantibiotics

Adjunctive Therapy for Oral Mucositis

Oragenics, in collaboration with Intrexon, is also in the process of developing live biotherapeutic products (LBP) to treat oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus.

Learn More About LBP

ProBiora Health, LLC Purchases Oragenics’ Oral Care Probiotics Business

Oragenics is excited to announce that it has reached an agreement with ProBiora Health, LLC to acquire its oral care probiotics business. Included in this acquisition are ProBiora3® and the Evora Oral Care Probiotics product line; EvoraPro®, EvoraPlus® and EvoraPet®.

Visit Probiorahealth.com Read the Press Release

Sign up for email updates

Be the first to receive breaking news

Sign Up

OG253 for C. difficile Infection

OG253 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including an animal model for Clostridium difficile infection in enteritis.

More on OG253 »

AG013 for Oral Mucositis

AG013 represents a promising product from a truly innovative platform for the prevention of oral mucositis in cancer patients.

More on AG013 »

ProBiora Health, LLC

ProBiora Health is focused on changing the way people think about benefits of oral and dental healthcare. Because a healthy mouth impacts more than just teeth and gums — recent research indicates it can have long-term effects on overall health as well. 

Learn more »

Investors Presentation

View our latest Corporate Presentation

View presentation »
Oragenics Pesentation
NYSE MKT OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Last Updated: